Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
暂无分享，去创建一个
S. Solomon | M. Pfeffer | G. Filippatos | J. McMurray | J. Rouleau | E. Braunwald | C. Granger | M. Senni | L. Køber | M. Petrie | D. Mann | A. Maggioni | P. Steg | B. Claggett | M. Lefkowitz | M. Čikeš | C. D. De Pasquale | P. van der Meer | I. Petrov | M. Schou | V. Menon | E. Lewis | Yinong Zhou | K. Jering | O. Berwanger | D. Sim | Alberto Fernández | U. Landmesser | Yi Wang | Béla Prof Merkely
[1] S. Solomon,et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics , 2021, European journal of heart failure.
[2] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[3] Stuart J Pocock,et al. The Primary Outcome Fails - What Next? , 2016, The New England journal of medicine.
[4] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.